Epigenetic approaches to reduce gum disease and rebuild lost jaw bone

Potentials of Epigenetic Molecules in Attenuating the Phenotypes of Periodontitis

NIH-funded research Tufts University Boston · NIH-11086151

Researchers are exploring whether drugs and microRNA tools that change gene activity can calm inflammation and help rebuild bone in adults with periodontitis.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionTufts University Boston NIH-funded
Lab location1 site (Boston, United States)
Project IDNIH-11086151 on NIH RePORTER

What this research studies

From a patient's point of view, the team is working with drugs that alter how genes are turned on and off and with small RNA molecules that promote bone formation to tackle the inflammation and bone loss of periodontitis. Most work is done in the lab using cells and mouse models to see which epigenetic agents best stop destructive inflammation and stimulate the body’s own bone-regenerating signals. The researchers previously found that a BET protein blocker called JQ1 reduced gum inflammation and bone loss in mice and are following up on that plus a specific microRNA (miR-335-5p) that encourages bone formation. The goal is to identify candidate therapies that could later move into human testing if results are promising.

Who could benefit from this research

Good fit: Adults (21+) with periodontitis, especially those with alveolar bone loss, would be the people who could ultimately benefit from therapies developed here.

Not a fit: Because the project is primarily laboratory and animal research, patients will not receive direct treatments from this grant during the current work.

Why it matters

Potential benefit: If successful, this work could lead to new treatments that reduce gum inflammation and restore lost alveolar bone, improving tooth stability and oral health.

How similar studies have performed: Related epigenetic and microRNA approaches have shown promise in other inflammatory and bone-related research, but applying BET inhibitors like JQ1 and miR-335-5p specifically to periodontitis is relatively new.

Where this research is happening

Boston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.